Compare ZGN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGN | SLNO |
|---|---|---|
| Founded | 1910 | 1999 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | N/A | 2014 |
| Metric | ZGN | SLNO |
|---|---|---|
| Price | $10.51 | $47.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $10.98 | ★ $110.90 |
| AVG Volume (30 Days) | 578.8K | ★ 1.3M |
| Earning Date | 09-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $2,248,050,499.00 | $98,675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.87 | $155.86 |
| P/E Ratio | $24.12 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.05 | $41.50 |
| 52 Week High | $11.00 | $90.32 |
| Indicator | ZGN | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 42.01 |
| Support Level | $10.26 | $47.01 |
| Resistance Level | $10.68 | $49.75 |
| Average True Range (ATR) | 0.27 | 2.37 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 50.00 | 8.91 |
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.